Publications
Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute. 2022. PMID: 36053203
Tempero M. Together Again! Journal of the National Comprehensive Cancer Network : JNCCN. 2022. PMID: 36075390
John Gordan, Adriana Pitea, Rigney E Turnham, Manon Eckhardt, Gwendolyn M Jang, Huat Lim, Alex L Choi, Sourav Bandyopadhyay, Danielle Swaney, Kevan Shokat, Trey Ideker, Nevan Krogan. Abstract PO017: HBV alters YAP regulation in liver cancer by remodeling PP2A complexes. Clinical Cancer Research. 2022. PMID:
Rigney E Turnham, Huat Chye Lim, Lucille Ferret, Katherine Lo, LeeAnn Wang, Alex Choi, John D Gordan. Abstract PO023: Uncovering hepatitis B virus-induced signaling changes in hepatocellular carcinoma. Clinical Cancer Research. 2022. PMID:
Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA oncology. 2022. PMID: 35834226
Huat Chye Lim, Rigney Turnham, Katherine Lo, Yeonjoo Hwang, John Gordan. Abstract PR01: Computational identification of targetable dependencies in hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) replication. Clinical Cancer Research. 2022. PMID:
Desai A, Velazquez AI, West HJ. Perioperative Therapy in Early-Stage Lung Cancer. JAMA oncology. 2022. PMID: 35900737
R. Aggarwal, L. Trihy, E. Hernandez Romero, S. Luch Sam, M. Rastogi, I. De Kouchkovsky, E.J. Small, F. Feng, D. Kwon, T. Friedlander, H.T. Borno, R. Bose, J. Chou, V.S. Koshkin, A. Desai, S. Feng, A. Angelidakis, M.S. Johnson, L. Fong, T. Hope. 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 2022. PMID:
T. Jindal, H. Han, P.S. Deshmukh, I. De Kouchkovsky, D. Kwon, H.T. Borno, V.S. Koshkin, A. Desai, R. Bose, J. Chou, T. Friedlander, E.J. Small, A. Angelidakis, M.S. Johnson, S. Feng, A. Patnaik, L. Fong, J. Alumkal, R. Aggarwal. 1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results. Annals of Oncology. 2022. PMID:
P.S. Deshmukh, I. De Kouchkovsky, L. Zhang, T. Jindal, K. Reyes, E. Hernandez Romero, E. Chan, A. Desai, H.T. Borno, D. Kwon, A. Wong, R. Bose, R. Aggarwal, S. Porten, L. Fong, E.J. Small, J. Chou, T. Friedlander, V.S. Koshkin. 1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies. Annals of Oncology. 2022. PMID:
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36041086
Charondo LB, Duque JB, Kirsch HE, Brondfield S. Maintaining Medical Student Motivation During Remote Clinical Learning. Academic medicine : journal of the Association of American Medical Colleges. 2022. PMID: 36044278
Chung A, Banbury B, Vignali M, Huang CY, Asoori S, Johnson R, Kurtz T, Arora S, Wong SW, Shah N, Martin TG, Wolf JL. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. British journal of haematology. 2022. PMID: 36041779
Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cort?s J, Di?ras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer. 2022. PMID: 36038616
Haas ND, Viele C, Paul SM, Abrams G, Smoot B, Melisko M, Levine JD, Miaskowski C, Kober KM. Polymorphisms in Cytokine Receptor and Regulator Genes are Associated with Levels of Exercise in Women Prior to Breast Cancer Surgery. Biological research for nursing. 2022. PMID: 36036249
Schwab ME, Shao S, Zhang L, Lianoglou B, Belter L, Jarecki J, Schroth M, Sumner CJ, MacKenzie T. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. Prenatal diagnosis. 2022. PMID: 36029101
Rugo HS, Bardia A, Marm? F, Cortes J, Schmid P, Loirat D, Tr?dan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. PMID: 36027558
Song H, Bucher S, Rosenberg K, Tsui M, Burhan D, Hoffman D, Cho SJ, Rangaswami A, Breese M, Leung S, Ventura MVP, Sweet-Cordero EA, Huang FW, Nijagal A, Wang B. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids. Nature communications. 2022. PMID: 36008377
Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nature biotechnology. 2022. PMID: 36008610
Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022. PMID: 36002574